Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:ESLANASDAQ:SLSNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$5.58-1.6%$6.15$4.09▼$17.24$100.91M0.69287,781 shs179,075 shsESLAEstrella Immunopharma$1.00+4.2%$0.97$0.63▼$3.23$36.17M0.4484,938 shs53,457 shsSLSSELLAS Life Sciences Group$1.40+4.5%$1.18$0.77▼$1.84$127.19M2.531.37 million shs2.44 million shsTHTXTheratechnologies$2.77-1.8%$1.81$1.08▼$3.13$127.37M1.11792,099 shs425,888 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals0.00%+9.41%-4.78%+0.90%-56.81%ESLAEstrella Immunopharma0.00%+26.01%+7.76%-11.50%-10.71%SLSSELLAS Life Sciences Group0.00%+7.69%+20.69%+38.61%-9.09%THTXTheratechnologies0.00%+9.92%+65.87%+61.52%+103.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals4.0447 of 5 stars3.41.00.04.73.04.20.0ESLAEstrella Immunopharma3.0326 of 5 stars3.55.00.00.03.61.70.0SLSSELLAS Life Sciences Group0.7312 of 5 stars0.04.00.00.02.30.00.6THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25209.14% UpsideESLAEstrella Immunopharma 3.00Buy$16.001,500.00% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ATHTXTheratechnologies 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ESLA, THTX, SLS, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/18/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.002/14/2025THTXTheratechnologiesResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/11/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.00 ➝ $21.002/11/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$66.59M1.79N/AN/A$5.24 per share1.06ESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/ASLSSELLAS Life Sciences Group$1M127.19N/AN/A($0.25) per share-5.60THTXTheratechnologies$88.67M1.44N/AN/A($0.45) per share-6.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)ESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%5/13/2025 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)THTXTheratechnologies-$23.96M-$0.08N/A39.57N/A-3.75%N/A-4.31%7/9/2025 (Estimated)Latest ESLA, THTX, SLS, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067N/AN/AN/AN/AN/A5/5/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.16N/AN/AN/A$15.96 millionN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47ESLAEstrella ImmunopharmaN/A0.750.75SLSSELLAS Life Sciences GroupN/A2.262.26THTXTheratechnologiesN/A1.080.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%ESLAEstrella Immunopharma0.35%SLSSELLAS Life Sciences Group17.38%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%ESLAEstrella Immunopharma55.10%SLSSELLAS Life Sciences Group1.20%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableSLSSELLAS Life Sciences Group1090.85 million69.54 millionNot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableESLA, THTX, SLS, and ENTA HeadlinesRecent News About These CompaniesTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comResearch Analysts Set Expectations for THTX FY2025 EarningsApril 18, 2025 | marketbeat.comWhat is Leede Financial's Estimate for THTX FY2026 Earnings?April 17, 2025 | marketbeat.comFY2026 Earnings Estimate for THTX Issued By Leede FinancialApril 17, 2025 | americanbankingnews.comLeede Financial Issues Pessimistic Outlook for THTX EarningsApril 17, 2025 | americanbankingnews.comShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 2,740.1%April 16, 2025 | marketbeat.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | businesswire.comTheratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the CompanyApril 11, 2025 | globenewswire.comFuture Pak submits proposals to acquire TheratechnologiesApril 11, 2025 | msn.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc. ...April 11, 2025 | gurufocus.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total ValueApril 11, 2025 | businesswire.comTheratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment SoursApril 9, 2025 | msn.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies receives FDA approval of PAS for EGRIFTA SV sBLAApril 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on DeckThe 3 Most Talked About Investments on WallStreetBets Right NowBy Leo Miller | April 2, 2025View The 3 Most Talked About Investments on WallStreetBets Right Now2 Ways to Win the Tarrif Trade: Toyota and TeslaBy Gabriel Osorio-Mazilli | April 7, 2025View 2 Ways to Win the Tarrif Trade: Toyota and TeslaTesla’s #1 Bull Cuts Target But Says It’s Still a BuyBy Sam Quirke | April 8, 2025View Tesla’s #1 Bull Cuts Target But Says It’s Still a BuyTesla Stock: What To Expect With Their Delivery Numbers ReportBy Sam Quirke | April 3, 2025View Tesla Stock: What To Expect With Their Delivery Numbers ReportESLA, THTX, SLS, and ENTA Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$5.58 -0.09 (-1.59%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.58 0.00 (-0.09%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Estrella Immunopharma NASDAQ:ESLA$1.00 +0.04 (+4.17%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.00 0.00 (-0.30%) As of 04/25/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.SELLAS Life Sciences Group NASDAQ:SLS$1.40 +0.06 (+4.48%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.07%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Theratechnologies NASDAQ:THTX$2.77 -0.05 (-1.77%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.73 -0.04 (-1.59%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
